ChronoScale Corporation Common Stock (NASDAQ:CHRN) Stock Price Up 9.6% – Still a Buy?

ChronoScale Corporation Common Stock (NASDAQ:CHRN)’s stock price shot up 9.6% during trading on Tuesday. The company traded as high as $16.08 and last traded at $16.04. Approximately 38,266 shares traded hands during trading, a decline of 83% from the average session volume of 223,190 shares. The stock had previously closed at $14.63.

Wall Street Analyst Weigh In

CHRN has been the subject of several analyst reports. Compass Point began coverage on shares of ChronoScale Corporation Common Stock in a research report on Friday, October 16th. They set a “buy” rating and a $25.00 price target for the company. Weiss Ratings cut ChronoScale Corporation Common Stock from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday. Finally, Northland Securities assumed coverage on ChronoScale Corporation Common Stock in a research note on Friday, September 18th. They set an “outperform” rating and a $32.00 target price on the stock. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, ChronoScale Corporation Common Stock currently has an average rating of “Hold” and a consensus price target of $21.00.

ChronoScale Corporation Common Stock Stock Performance

The business’s fifty day moving average price is $19.20 and its 200-day moving average price is $15.81. The stock has a market cap of $2.47 billion, a PE ratio of -3.93 and a beta of 0.98. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.30 and a current ratio of 0.30.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last released its quarterly earnings data on Wednesday, October 14th. The company reported ($0.29) earnings per share for the quarter. The company had revenue of $41.48 million for the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 66.16%. As a group, equities research analysts forecast that ChronoScale Corporation Common Stock will post -0.49 EPS for the current fiscal year.

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.